(NASDAQ: FTRE) Fortrea Holdings's forecast annual revenue growth rate of 0.74% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.83%.
Fortrea Holdings's revenue in 2024 is $2,774,800,000.On average, 4 Wall Street analysts forecast FTRE's revenue for 2024 to be $242,242,743,600, with the lowest FTRE revenue forecast at $242,163,090,000, and the highest FTRE revenue forecast at $242,369,579,400. On average, 4 Wall Street analysts forecast FTRE's revenue for 2025 to be $244,852,834,200, with the lowest FTRE revenue forecast at $241,920,900,000, and the highest FTRE revenue forecast at $248,110,200,000.
In 2026, FTRE is forecast to generate $256,380,540,000 in revenue, with the lowest revenue forecast at $254,756,162,700 and the highest revenue forecast at $258,336,897,000.